Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jun 15;18(1):277.
doi: 10.1186/s13063-017-2015-3.

Reducing the rate and duration of Re-ADMISsions among patients with unipolar disorder and bipolar disorder using smartphone-based monitoring and treatment - the RADMIS trials: study protocol for two randomized controlled trials

Maria Faurholt-Jepsen  1   2 , Mads Frost  3 , Klaus Martiny  4   5 , Nanna Tuxen  4   5 , Nicole Rosenberg  4   5 , Jonas Busk  6 , Ole Winther  6 , Jakob Eyvind Bardram  6   7 , Lars Vedel Kessing  4   5
Affiliations
Randomized Controlled Trial

Reducing the rate and duration of Re-ADMISsions among patients with unipolar disorder and bipolar disorder using smartphone-based monitoring and treatment - the RADMIS trials: study protocol for two randomized controlled trials

Maria Faurholt-Jepsen et al. Trials. .

Abstract

Background: Unipolar and bipolar disorder combined account for nearly half of all morbidity and mortality due to mental and substance use disorders, and burden society with the highest health care costs of all psychiatric and neurological disorders. Among these, costs due to psychiatric hospitalization are a major burden. Smartphones comprise an innovative and unique platform for the monitoring and treatment of depression and mania. No prior trial has investigated whether the use of a smartphone-based system can prevent re-admission among patients discharged from hospital. The present RADMIS trials aim to investigate whether using a smartphone-based monitoring and treatment system, including an integrated clinical feedback loop, reduces the rate and duration of re-admissions more than standard treatment in unipolar disorder and bipolar disorder.

Methods: The RADMIS trials use a randomized controlled, single-blind, parallel-group design. Patients with unipolar disorder and patients with bipolar disorder are invited to participate in each trial when discharged from psychiatric hospitals in The Capital Region of Denmark following an affective episode and randomized to either (1) a smartphone-based monitoring system including (a) an integrated feedback loop between patients and clinicians and (b) context-aware cognitive behavioral therapy (CBT) modules (intervention group) or (2) standard treatment (control group) for a 6-month trial period. The trial started in May 2017. The outcomes are (1) number and duration of re-admissions (primary), (2) severity of depressive and manic (only for patients with bipolar disorder) symptoms; psychosocial functioning; number of affective episodes (secondary), and (3) perceived stress, quality of life, self-rated depressive symptoms, self-rated manic symptoms (only for patients with bipolar disorder), recovery, empowerment, adherence to medication, wellbeing, ruminations, worrying, and satisfaction (tertiary). A total of 400 patients (200 patients with unipolar disorder and 200 patients with bipolar disorder) will be included in the RADMIS trials.

Discussion: If the smartphone-based monitoring system proves effective in reducing the rate and duration of re-admissions, there will be basis for using a system of this kind in the treatment of unipolar and bipolar disorder in general and on a larger scale.

Trial registration: ClinicalTrials.gov, ID: NCT03033420 . Registered 13 January 2017. Ethical approval has been obtained.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and outcome assessments in the RADMIS trials
Fig. 2
Fig. 2
Flow diagram of the RADMIS trials
Fig. 3
Fig. 3
The Monsenso self-assessment system. Screenshot of the smartphone-based self-assessment
Fig. 4
Fig. 4
The Monsenso self-assessment system. Screenshot of the smartphone-based self-assessment of mood
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RMA, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543–52. doi: 10.1001/archpsyc.64.5.543. - DOI - PMC - PubMed
    1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (ncs-r) JAMA. 2003;289(23):3095–105. doi: 10.1001/jama.289.23.3095. - DOI - PubMed
    1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–86. doi: 10.1016/S0140-6736(13)61611-6. - DOI - PubMed
    1. Olesen J, Gustavsson A, Svensson M, Wittchen H-U, Jönsson B. on behalf of the CDBE2010 study group, et al. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62. doi: 10.1111/j.1468-1331.2011.03590.x. - DOI - PubMed
    1. Arbejdsgruppe under Regeringens udvalg om Psykiatri. Indsatsen for mennesker med psykiske lidelser- kapacitet, sammenhæng og strktur. Bilagsrapport 1. Afrapportering fra Arbejdsgruppemøde under Regeringens udvalg om Psykiatri. 2013.

Publication types

MeSH terms

Associated data